ISTH 2023 | The role of anticoagulation and antiplatelet therapy in hereditary hemorrhagic telangiectasia

Name: The role of anticoagulation and antiplatelet therapy in hereditary hemorrhagic telangiectasia
Uploaded: 2023-06-25T00:00:00Z
Duration: 2 min 55 s

Hanny Al-Samkari • 25 Jun 2023

ISTH 2023

Hereditary Hemorrhagic Telangiectasia Rare Diseases

Hereditary hemorrhagic telangiectasia (HHT) is a bleeding disorder which can also carry an increased risk of thrombosis. Hanny Al-Samkari, MD, Massachusetts General Hospital, Boston, MA, explains the complexity of this disorder and discusses the results from a study of a large cohort of patients with HHT who required antithrombotic therapies, such as anticoagulation and antiplatelet therapies. This study aims to establish a baseline understanding of the potential complications of antithrombotic therapy for these patients, which could inform more effective approaches in the future. This interview took place at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH), held in Montréal, Canada.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Research funding to institution (Agios, Amgen, Novartis, Vaderis, Sobi); Consultancy (Agios, Novartis, Moderna, Rigel, Argenx, Pharmacosmos, Sobi, Forma)